Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  1. Outputs

Glucometrics and device satisfaction in children and adolescents with type 1 diabetes using different treatment modalities: A multicenter real-world observational study

Academic Article
Publication Date:
2024
Short description:
Glucometrics and device satisfaction in children and adolescents with type 1 diabetes using different treatment modalities: A multicenter real-world observational study / Cherubini, V., Fargalli, A., Arnaldi, C., Bassi, M., Bonfanti, R., Patrizia Bracciolini, G., Cardella, F., Dal Bo, S., Delvecchio, M., Di Candia, F., Franceschi, R., Maria Galassi, S., Gallo, F., Graziani, V., Iannilli, A., Mameli, C., Marigliano, M., Minuto, N., Monti, S., Mozzillo, E., et al.. - In: DIABETES RESEARCH AND CLINICAL PRACTICE. - ISSN 0168-8227. - 210:111621(2024). [10.1016/j.diabres.2024.111621]
abstract:
Aims: To analyze metabolic outcomes, diabetes impact and device satisfaction in children and adolescents with type 1 diabetes in Italy who used different treatment modalities for diabetes care in a real-life context. Methods: In this multicenter, nationwide, cross-sectional study, 1464 participants were enrolled at a routine visit. The following treatment modalities were considered MDI + SMBG; MDI + CGM; Sensor Augmented Pump Therapy; predictive management of low glucose; Hybrid Closed Loop (HCL); Advanced Hybrid Closed Loop (AHCL). Health related quality of life was evaluated by the Italian version of the Diabetes Impact and Device Satisfaction Scale (DIDS) questionnaire. Results: Patients treated with AID systems were more likely to have HbA1c ≤ 6.5 %, higher percentage of time with glucose levels between 70 and 180 mg/dL, lower percentage of time with glucose levels above 180 mg/dL, higher device satisfaction, and reduced impact of diabetes. All the therapeutic modalities with respect to MDI + CGM, except for MDI + SMBG, contributed to increase the device satisfaction. HCL and AHCL respect to MDI + CGM were associated with lower diabetes impact. Conclusion: Real-life use of automated insulin delivery systems is associated with reduced type 1 diabetes impact, increased device satisfaction, and achievement of glycemic goals.
Iris type:
1.1 Articolo in rivista
List of contributors:
Cherubini, V.; Fargalli, A.; Arnaldi, C.; Bassi, M.; Bonfanti, R.; Patrizia Bracciolini, G.; Cardella, F.; Dal Bo, S.; Delvecchio, M.; Di Candia, F.; Franceschi, R.; Maria Galassi, S.; Gallo, F.; Graziani, V.; Iannilli, A.; Mameli, C.; Marigliano, M.; Minuto, N.; Monti, S.; Mozzillo, E.; Pascarella, F.; Predieri, B.; Rabbone, I.; Roppolo, R.; Schiaffini, R.; Tiberi, V.; Tinti, D.; Toni, S.; Scaramuzza, A.; Vestrucci, B.; Gesuita, R.
Authors of the University:
BONFANTI RICCARDO
Handle:
https://iris.unisr.it/handle/20.500.11768/160458
Full Text:
https://iris.unisr.it//retrieve/handle/20.500.11768/160458/229004/PIIS0168822724001050.pdf
Published in:
DIABETES RESEARCH AND CLINICAL PRACTICE
Journal
  • Overview

Overview

URL

https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(24)00105-0/fulltext
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.7.2.0